- Home
- ACRS vs NEXN Comparison
ACRS vs NEXN Comparison
Compare ACRS & NEXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRS | NEXN |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 314.2M | 367.2M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ACRS | NEXN |
|---|---|---|
| Price | $3.19 | $6.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $9.75 | ★ $12.14 |
| AVG Volume (30 Days) | ★ 3.1M | 334.7K |
| Earning Date | 02-23-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 237.45 |
| EPS | N/A | ★ 0.62 |
| Revenue | $15,742,000.00 | ★ $376,353,000.00 |
| Revenue This Year | N/A | $5.43 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.82 |
| Revenue Growth | N/A | ★ 7.80 |
| 52 Week Low | $1.05 | $5.60 |
| 52 Week High | $4.89 | $12.60 |
Technical Indicators
Market Signals| Indicator | ACRS | NEXN |
|---|---|---|
| Relative Strength Index (RSI) | 48.13 | 47.88 |
| Support Level | $3.25 | $5.84 |
| Resistance Level | $3.78 | $6.20 |
| Average True Range (ATR) | 0.25 | 0.33 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 13.52 | 39.20 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About NEXN Nexxen International Ltd. American Depository Shares
Nexxen International Ltd is a globalized and flexible advertising technology platform with deep expertise in data and advanced TV that helps empower advertisers, agencies, digital publishers and broadcasters to achieve desired outcomes, including increased efficiency and returns, across the media supply chain. It is a demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with and exclusive data at its core. Company operates in America, APAC, EMEA, regions, with majority revenue from America.